Exposure-Response Evaluation of IV Artesunate in Children With Severe Malaria
Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
In this study, Ugandan children who are diagnosed with severe malaria will receive
intravenous (IV) artesunate per World Health Organization (WHO) guidelines.
Phase:
Phase 4
Details
Lead Sponsor:
Emory University
Collaborators:
Makerere University National Institute of Allergy and Infectious Diseases (NIAID) University of Maryland, Baltimore